Skip to main content
. 2016 Jun 24;23(13):4169–4177. doi: 10.1245/s10434-016-5286-0

Fig. 2.

Fig. 2

Analysis of the patterns of response in T-VEC-treated patients in OPTiM. * Includes three patients with PPR in existing lesions who may have also developed new lesions. PPR progression prior to response, GM-CSF granulocyte–macrophage colony-stimulating factor, DR durable response